Product Name: MEK4 (77-83) pS80
Product Number: PE-04ANT99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: MEK4 (77-83) pS80

Product Use: Services as a blocking peptide for use with the MKK4-pS80 rabbit polyclonal antibody (Cat. No.: AB-PK716) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the N-terminal portion of the kinase before the kinase catalytic domain. Phosphorylation inhibits phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RTH-pS-IES

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1082.08 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: MEK4 - pS80 phosphosite-specific antibody (Cat. No.: AB-PK716)

Scientific Background: MKK4 (MAP2K4, MEK4) is a dual specificity protein kinase of the STE group and STE7 family Phosphorylation of S257 and T261 increases phosphotransferase activity. Phosphorylation of S80 inhibits its phosphotransferase activity. It acts as a critical component in the MAP kinase (MAPK) and the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathways. It has a role in maintaining peripheral lymphoid homeostasis and apoptosis. Mutations and deletions of this genes leads to dysregulated JNK signalling and promotes oncogenesis. MKK4 appears to be a tumour suppressor protein (TSP), but it may also promote metastasis. Cancer-related mutations in human tumours point to a loss of function of the protein kinase. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. However, significantly elevated expression of MKK4 has been observed in invasive pancreatic cancer specimens, indicating a possible role for the protein in tumourigenesis. MKK4 over-expression is correlated with increased expression of heat shock protein 27 (HSP27) and matrix metalloproteinase 2 (MMP-2) protein, which are required for the increased invasive phenotype of the cells. Therefore, MKK4 appears to have an important role in the promotion of metastasis in pancreatic cancer cells. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.